Brought to you by 
Specialty pharmaceuticals company SciClone taken private by investor consortium
16 Oct 2017
Executive Summary
SciClone Pharmaceuticals Inc. (specialty pharmaceuticals) agreed to be acquired by Silver Biotech Investment Limited, an investor consortium consisting of GL Capital Management, Bank of China Group, CDH Investments, Ascendent Capital Partners and Boying for $11.18 per share (16.1% premium) in cash or approximately $605mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Specialty pharmaceuticals company SciClone taken private by investor consortium
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice